October 06-29

THE ULTIMATE WEBINAR SERIES IN GENE EXPRESSION STUDIES

Register here

applied biosystems
by Thermo Fisher Scientific

WILEY
Amit Mandal    ORCID iD: 0000-0003-0986-5927

Tom Hosack    ORCID iD: 0000-0003-1740-109X

Vitamin D status may indeed be a prognosticator for morbidity and mortality in patients with COVID-19

Amit K J Mandal¹

Vadir Baktash¹

Tom Hosack¹

Koenraad Van den Abbeele¹

Constantinos G Missouris¹,²

¹Wexham Park Hospital, Frimley Health NHS Foundation Trust, UK

²University of Cyprus Medical School, Nicosia, Cyprus

Corresponding Author

Prof C G Missouris MD, FRCP, FACP

Departments of Cardiology and Internal Medicine

Wexham Park Hospital

Frimley health NHS Foundation Trust

Wexham Street, Slough UK

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jmv.26569.

This article is protected by copyright. All rights reserved.
TO THE EDITOR:

We read with interest the systemic review and meta-analysis by Munchi et al. [1] of emerging evidence that vitamin D deficiency is associated with poorer outcomes and prognosis in patients with COVID-19 and would like to report our experience in the United Kingdom (UK). We recently conducted a prospective cohort study to assess the importance of vitamin D (25-OH-D) deficiency in older patients with COVID-19 [2]. Our significant findings were that patients with low concentrations of 25OH-D (≤30nmol/l) demonstrated clinically relevant, elevated markers of cytokine release syndrome and were more likely to become hypoxic and require ventilatory support. Although our study was underpowered to detect a mortality difference between deficient and replete groups, our data support that vitamin D status may be a surrogate prognosticator for morbidity and mortality in patients with COVID-19.

It is established that there is a complex interplay between vitamin D and various components of the innate and adaptive immune responses to both bacterial and viral infections. Alongside it’s anti-inflammatory properties, vitamin D provides a protective role for alveolar epithelial and endothelial cells and reduces vascular permeability. In addition, vitamin D enhances ACE-2 expression which is actually favourable against acute lung injury [3]. Whether the link between vitamin D deficiency and requirement of ventilatory support observed in our cohort represents a causal relationship is unclear. However, disruption of one or more of these defensive pathophysiological processes may explain the association.

Mortality and hospitalisation rates for COVID-19 appear higher in northern latitude countries compared to those closer to the equator [4] and this supports an interrelation between vitamin D deficiency and adverse prognosis. For special consideration are older adults, particularly those who are institutionalised, who are inherently
vulnerable to vitamin D insufficiency because of inadequate sun exposure and dietary imbalance and may have worse outcomes with COVID-19. In the UK, there is also growing concern that the Black, Asian and Minority Ethnic (BAME) community are more susceptible to severe presentations of COVID-19 as a result of higher skin melanin content and reduced synthesis of vitamin D.

Regardless of the aetiology, vitamin D deficiency is readably diagnosable and correctable. On the basis of this reasoning and pending results of trials evaluating vitamin D supplementation and appropriate dosing within the context of COVID-19, efforts to manage vitamin D deficiency should be encouraged.

References


